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Abstract 
The present work investigates the feasibility of fabricating chitosan (CS)-levofloxacin (LOF) nanoparticles by ionotropic gelation 
technology. An orthogonal experiment was designed to optimize its preparing parameters and multi-index comprehensive weighed score 
analysis method was used to study the effects of various factors including concentration of CS, concentration of tripolyphosphate (TPP), 
mass ratio of CS to TPP, and mass ratio of CS to LOF on the properties of nanoparticles. The particles prepared under optimal condition 
of 2mg/ml CS concentration, 2mg/ml TPP concentration, 0.5:1 mass ratio of oil to water and 4:1 mass ratio of CS to TPP had 140nm 
diameter, 0.95 span, 6.13% loading capacity (LC) and 24.91% encapsulation efficiency (EE). In vitro release profile showed that LOF 
released fast initially and then slowly with T90 occurring at 76.5h. Future studies should focus on antibacterial and biocompatible 
properties in order to evaluate its potential as sustainable delivery system. 
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1. Introduction 
Levofloxacin (LOF) is one of the third generations of fluoroquinolones with broad-spectrum antibacterial activity. It is 
effective to either gram positive or gram negative bacteria, thus is widely used for controlling urinary tract, respiratory 
tract, skin and soft tissue infections. However, it requires frequent dosing to maintain therapeutic effect because of its short 
biological half-life and greatly varying pharmaceutical concentrations of blood. The normal dosage regimen of this drug is 
100 mg, usually administered three times a day [1]. But in some severe cases, long-term therapy might also be required. 
Sustained delivery LOF preparation can be helpful to conserve and maintain effective drug concentration, reduce dosing 
times, improve compliance and decrease side effects, and thus, optimize drug therapy.  
Many efforts towards developing LOF sustained delivery system in the form of capsulate [2], filament [3], microsphere 
[4-6], and nanoparticle [7,8] have been made during the past few years. Since nanoparticle has decreased particle size, 
increased surface area, enhanced reactivity, promoted drug dissolution, reformed targeting, reduced toxicity and improved 
sustained-release efficacy, and therefore it could offer numerous advantages over the conventional dosage forms and 
attracted a considerable attention recently [9].  
Compared with other carriers, chitosan (CS) has many advantages for controlling drugs delivery, particularly for 
microsphere or nanoparticle delivery system. These include its ability to control the release of active agents, avoiding the 
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use of hazardous organic solvents while fabricating particles since it is soluble in aqueous acidic solution, being a linear 
polyamine containing a number of free amine groups that are readily available for crosslinking, and so on [10-15]. 
Among various CS nanoparticle preparation methods, ionotropic gelatin is a simpler, milder and safer one since CS 
nanoparticles are formed by electrostatic interaction, instead of chemical crosslinking. Tripolyphosphate (TPP) is such a 
polyanion that can interact with the cationic CS by electrostatic forces. In this method, CS is dissolved in aqueous acidic 
solution to obtain the cations of CS. This solution is then added dropwise under constant stirring into TPP solution. Due to 
the complex between oppositely charged species, CS undergoes ionic gelation and precipitates to form spherical particles 
[16]. 
After Bodmeier reported the preparation of CS-TPP complex by dropping CS droplets into a TPP solution [17], many 
researchers have explored its potential pharmaceutical usage, especially for nanoparticle sustainable release system. 
Previous studies showed that the physicochemical properties, stability and drug release property of those nanoparticles 
were mostly affected by the molecular weight (MW), deacetylation degree (DD) and concentration of CS, concentration of 
TPP, the ratio of CS to TPP, and drug content [18-20]. However, those particles have never been tried on loading LOF 
until now. 
In this paper, CS with 98000 of MW and 87% of DD was chosen as the carrier of LOF. An orthogonal test was 
designed to optimize ionic gelatin preparing parameters for nanoparticles, and the effects of various factors, including 
concentration of CS, concentration of TPP, mass ratio of CS to TPP, and mass ratio of CS to LOF, on the comprehensive 
properties of nanoparticles, involving particle size, span, loading capacity (LC) and encapsulation efficiency (EE) were 
evaluated based on the multi-index comprehensive weighed score analysis method. Then, the physical-chemical and drug 
release property were tested to verify its potential as sustainable delivery system.  
2. Materials and Methods 
2.1. Materials 
LOF (batch number: 200801012, Zhejiang East Pharmaceutical Co., China); CS (MW: 98000; DD> 87%, Shandong 
Aokang Biological Technology Co., China); TPP˄Sigma, USA˅ ; glacial acetic acid, hydrochloric acid (Tianjin 
Chemical Reagent Co., China). 
2.2. Preparation of nanoparticles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Schematic drawing of CS-TPP nanoparticle formation by ionotropic gelation 
Suitable amount of LOF was put into 20ml of 1l2 mg/ml CS acetic solution under 500 rpm stirring rate until 
dissolution. This solution was then added dropwise into certain amount of 1l2 mg/ml TPP solution, and pH was adjusted 
chitosan positive charge of chitosan 
levofloxacin 
ionic interaction 
hydrogen bond between  chitosan molecule 
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into the range from 4.5 to 6. Then nanoparticle suspensions can be formed and its mechanism of formation was 
demonstrated by Fig.1. 
2.3. Morphological detection 
The nanoparticle suspension was drawn into a piece of glass slide and observed under biological microscopy with 1000 
magnification. For TEM, the nanoparticle solution was dropped on copper grids and dried overnight at room temperature 
for viewing (Philips EM400ST).  
2.4. Size of nanoparticles  
Nanoparticles were diluted by distilled water to form dispersion. The sizes of those nanoparticles in fluid were 
measured by laser particle size analyzer at 25ć. The span was calculated by the following formula: 
Span=˄D90-D10˅/D50                                                                                                                                  (1) 
Where D90ǃD50 and D10 designates that the particle size for which 90%ǃ50% and 10% of the particles are smaller 
than this volume respectively. 
2.5. Standard curve of LOF 
About 5mg LOF was weighed accurately and placed into 50 ml volumetric flask. Then PBS solution with pH 7.4 was 
added into the flask to make 0.1mg/mL LOF stock solution. Then the stock solution was diluted into series of standard 
solutions with LOF concentrations of 3Ȳg/ml, 6Ȳg/ml, 9Ȳg/ml, 12Ȳg/ml and 15Ȳg/ml respectively. The absorbance of 
each solution at 293nm was determined by UV spectrophotometer with PBS as blank. Then LOF standard curve was 
drawn and the corresponding data was regressed as standard equation. 
2.6. LC and EE of nanoparticles 
The LC and EE of nanoparticles were determined by separation of nanoparticles from the aqueous medium containing 
free drug by centrifugation at 14000rpm for 30 min. The absorbance of free LOF in the supernatant was measured by UV 
at 293nm and the amount of LOF was calculated according to above standard curve. The sedimentation was then 
lyophilized and weighted. The LC and EE of the nanoparticles were calculated as follows: 
LC=(T-F)/M                                                                                                                                                       (2) 
Where T is total amount of LOF added into CS solution, F is free LOF amount in the supernatant, M is the total 
amount of nanoparticles. 
EE=(T-F)/T   (3) 
Where T and  F are the same as the descriptions of equation (2). 
2.7. In Vitro release behavior 
0.01g nanoparticles were placed in a dialysis bag and put into a cell containing 100ml of pH 7.4 PBS solution under the 
condition of 37ć and 100 rpm agitation. Subsequently series of 1ml dialysis solutions were withdrawn into 100 ml 
volumetric flask at specific time points (0.5 h, 1 h, 3 h, 5 h, 7 h, 10 h, 12 h, 24 h, 48 h, 72 h, 120h) and diluted. Then their 
absorbencies at 293nm were determined as above. The release dosage at each moment was calculated and drawn into 
cumulative release curve. 
2.8. Statistics 
Each experiment was performed triply and each data was expressed as an average. 
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3. Results and Discussion 
3.1. Data analysis of orthogonal test
L34 orthogonal experiments were designed. The four factors, such as CS concentration (A), TPP concentration (B), mass 
ratio of CS to LOF (C), mass ratio of CS to TPP (D), and their three levels were shown in Table 1.  
In order to assess synthetically the effects of various factors on the combination properties of the nanoparticles, multiple 
index comprehensive weight analysis method was employed to deal with the data, where weighted coefficients of particle 
size (S1), span (S2), LC (S3) and EE (S4) were set as 0.2Υ0.1Υ0.3 and 0.4 respectively based on standard derivation and 
expert advice methodology.  
The orthogonal experimental conditions and results were shown in Table 2. Since the region of optimality were referred 
to as a low particle size and span value, and a high LC and EE value. So the minimum value of either particle size or span 
among total column data was both set as 100 point, and similarly, the maximum value of LC or EE were set as 100 point. 
Then each result of size, span, LC and EE was changed into a certain point, and the combination score of each numbered 
experiment can be calculated referred to respective weighted coefficients, which was listed in the last column of Table 2. 
Table 1 Factors and levels of orthogonal test 
Levels 
Factors 
A 
Concentration of CS
/mg/ml 
B 
Concentration of TPP 
/mg/ml 
C 
Mass ratio of CS to 
LOF 
D 
Mass ratio of CS to 
TPP 
1 1 1 0.5:1 3:1 
2 1.5 1.5 1:1 4:1 
3 2 2 2:1 5:1 
The extreme difference of each factor (Rj value) was also listed in the last row of Table 2. These data indicate that the 
significance of four factors was in the order of A, C, D, B, which means concentration of CS, mass ratio of CS to LOF, 
mass ratio of CS to TPP affected greatly and concentration of TPP influenced slightly on the combination qualities of 
nanoparticles. In addition, by comparing the values of ĉj, Ċj, ċj, the significance of each factor can be concluded as 
following: ċA>ĊA>ĉAˈċB>ĉB>ĊBˈĉC>ċC>ĊC, ĊD>ċD>ĉD. Therefore A3B3C1D2, which corresponds to 
2mg/ml CS concentration, 2mg/ml TPP concentration, 0.5:1 mass ratio of CS to LOF, and 4:1 mass ratio of CS to TPP, 
was regarded as the optimal combination parameters.  
Table 2. Results of orthogonal experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NO. 
Factors Experiment results Combination 
evaluations 
/points A B C D S1(nm) S2 
S3 
(%) 
S4 
(%) 
1 1 1 1 1 249.0 2.37 5.32 16.24 39.80 
2 1 2 2 2 157.4 0.99 3.73 15.27 35.67 
3 1 3 3 3 112.7 0.77 2.14 19.36 38.66 
4 2 1 2 3 276.7 4.72 5.95 21.08 47.73 
5 2 2 3 1 272.2 4.97 4.27 26.55 51.12 
6 2 3 1 2 251.5 1.77 8.56 27.53 79.90 
7 3 1 3 2 779.2 1.73 7.31 34.17 72.35 
8 3 2 1 3 410.0 1.19 7.83 25.53 68.59 
9 3 3 2 1 310.2 6.07 6.44 22.74 49.98 
ĉj 114.1 159.9 188.3 140.9      
Ċj 178.7 155.4 133.4 187.9      
ċj 190.9 168.5 162.1 155.0      
Rj 76.8 13.1 54.9 47.0      
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3.2.  Morphology of nanoparticles 
LOF-loaded CS nanoparticles prepared under conditions of No.7 and No.8 in Table 1 were demonstrated in Fig.2. 
These nanoparticles were dispersed very well in suspensions with average diameters ranging from 410 to 779 nm. The 
TEM photos showed nanoparticles prepared under optimal condition had spherical biconcave in shape (Fig.3)., Their 
average diameter and span were 140nm and  0.95 respectively. 

Fig.2. Photomicrographs of LOF-loaded CS nanoparticles (A) No.7 group (B) No.8 group 



 
 
 
 
 
 
 
Fig.3. TEM of LOF-loaded CS nanoparticles 
3.3. Particle size, LC and EE of nanoparticles 
The size distributions of nanoparticles prepared under No.3 and No.7 were shown in Fig. 4, which demonstrated that 
the average diameters of No.3 and No.7 were 112.7nm and 779.2nm, and their spans were 0.77 and 1.73 respectively. Fig. 
4(A) also showed that nanoparticles prepared under No.3 parameters had only one size of particles, whose diameters were 
from 69nm to 172nm. While the nanoparticles prepared under No.7 parameters had three compositions of particles, whose 
diameters were in the ranges of 1.0nm-1.8nm, 42nm-178nm and 562 nm-1778 nm respectively (Fig.4 (B)). The three 
groups of particles had huge differences between particle sizes, which determined the span value of No.7 was much greater 
than that of No.3. Perhaps the relative high concentration of CS caused the increased viscose of reactive solution, which 
resulted in not uniform particle formed.  
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Fig. 4. Dynamic Light Scattering results of CS-LOF nanoparticles (A) No.3 group (B) No.7 group 
The standard curve of LOF was shown in Fig. 5, where the scattered dots indicated the experimental data and the red 
line indicated the regressed equation: 
A=0.0697Cˉ0.0563 (r2=0.9907)                                                                                                                      (4) 
Where A indicates absorbance of nanoparticle dissolution at 293nm; C indicates the LOF concentration and r2 is 
related factors. The 0.9907 of r2 value implies that the regressed equation matched well with the experimental data, 
and the equation can be used to assess the drug contents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.5. Standard curve of LOF 
Based on Fig.5, LC and EE values of nanoparticles prepared under the optimal condition can be calculated as 6.13% 
and 24.91% respectively. 
3.4. In vitro release behavior
The relationship between percentage of cumulative release and releasing time was demonstrated in Fig. 6. It can be 
observed that the initial release rate was relatively high with cumulative release percentage up to 10% within 0.5 h, 21.7% 
at 3h, 50% at 7.5h, 60% at 10h, 72% at 12h, while the subsequent release rates decreased gradually with about 85% at 24h, 
90% at 56.5h. The initial higher release rates might be caused by the dissolution of surface drug from nanoparticles. At 
slight longer time, drug release might be mainly controlled by the diffusion process, which was much slower than the 
initial dissolution release. The drug release test indicated that the nanoparticles prepared under optimal condition could 
release LOF gradually up to three days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. The curve of CS-LOF nanoparticles in vitro release 
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4. Conclusion 
CS-LOF nanoparticles can be fabricated by ionotropic gelation method. The optimal preparation parameters were 
2mg/ml CS concentration, 2mg/ml TPP concentration, 0.5:1 mass ratio of CS to LOF, and 4:1 mass ratio of CS to TPP. 
The optimal nanoparticles had spherical morphology, 140nm diameter, 0.95 span, 6.13% LC, and 24.91% EE. Thus 
prepared nanoparticles could release LOF gradually within 3 days. Antibacterial and biocompatible properties should be 
carried out in near future to evaluate its potential as sustainable delivery system. 
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